Correlation Between Rigel Pharmaceuticals and Immunitybio

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Rigel Pharmaceuticals and Immunitybio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Rigel Pharmaceuticals and Immunitybio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Rigel Pharmaceuticals and Immunitybio, you can compare the effects of market volatilities on Rigel Pharmaceuticals and Immunitybio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Rigel Pharmaceuticals with a short position of Immunitybio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Rigel Pharmaceuticals and Immunitybio.

Diversification Opportunities for Rigel Pharmaceuticals and Immunitybio

0.45
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Rigel and Immunitybio is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Rigel Pharmaceuticals and Immunitybio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunitybio and Rigel Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Rigel Pharmaceuticals are associated (or correlated) with Immunitybio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunitybio has no effect on the direction of Rigel Pharmaceuticals i.e., Rigel Pharmaceuticals and Immunitybio go up and down completely randomly.

Pair Corralation between Rigel Pharmaceuticals and Immunitybio

Given the investment horizon of 90 days Rigel Pharmaceuticals is expected to generate 1.03 times more return on investment than Immunitybio. However, Rigel Pharmaceuticals is 1.03 times more volatile than Immunitybio. It trades about 0.18 of its potential returns per unit of risk. Immunitybio is currently generating about 0.08 per unit of risk. If you would invest  1,345  in Rigel Pharmaceuticals on August 25, 2024 and sell it today you would earn a total of  1,259  from holding Rigel Pharmaceuticals or generate 93.61% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Rigel Pharmaceuticals  vs.  Immunitybio

 Performance 
       Timeline  
Rigel Pharmaceuticals 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Rigel Pharmaceuticals are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating technical and fundamental indicators, Rigel Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.
Immunitybio 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Immunitybio are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Immunitybio showed solid returns over the last few months and may actually be approaching a breakup point.

Rigel Pharmaceuticals and Immunitybio Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Rigel Pharmaceuticals and Immunitybio

The main advantage of trading using opposite Rigel Pharmaceuticals and Immunitybio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Rigel Pharmaceuticals position performs unexpectedly, Immunitybio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunitybio will offset losses from the drop in Immunitybio's long position.
The idea behind Rigel Pharmaceuticals and Immunitybio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Complementary Tools

Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites